Journal article
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Abstract
BACKGROUND: Active-comparator trials are important to inform patient and physician choice. We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn's disease.
METHODS: We conducted a randomised, double-blind, parallel-group, active-comparator, phase 3b trial (SEAVUE) at 121 hospitals or private practices in 18 countries. We included …
Authors
Sands BE; Irving PM; Hoops T; Izanec JL; Gao L-L; Gasink C; Greenspan A; Allez M; Danese S; Hanauer SB
Journal
The Lancet, Vol. 399, No. 10342, pp. 2200–2211
Publisher
Elsevier
Publication Date
June 2022
DOI
10.1016/s0140-6736(22)00688-2
ISSN
0140-6736